A Study of Diroximel Fumarate (DRF) in Adult Participants From the Asia-Pacific Region With Relapsing Forms of Multiple Sclerosis (RMS)
第3相
完了
NCT05083923
| 対象疾患 | Relapsing Forms of Multiple Sclerosis |
|---|
| 相 | 第3相 |
|---|
| スポンサー | Biogen |
|---|
| ステータス | 完了 |
|---|
| 参加者数 | 136 名 |
|---|
| 介入（薬剤） | Diroximel fumarate |
|---|
| 開始日 | 2021年11月18日 |
|---|
| 完了日 | 2024年9月11日 |
|---|
| 結果公開日 | 2025年10月24日 |
|---|
概要
The primary objectives of this study are to determine the safety and tolerability of DRF administered for up to 24 weeks in adult East Asian participants with RMS (Part 1) and to determine the safety and tolerability of DRF administered for up to 48 weeks in adult East Asian participants with RMS (Part 2). The secondary objective of this study is to evaluate the pharmacokinetic(s) (PK) of DRF metabolites (monomethyl fumarate \[MMF\] and 2-hydroxyethyl succinimide \[HES\]) following multiple doses of DRF in a subset of adult East Asian participants with RMS (Part 1).
Part 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)
Baseline (Day 1) up to Week 24 (for prematurely discontinued participants, AEs were reported up to 2 weeks post discontinuation) · Participants
| Cohort 1: Japanese Participants | 50 Participants |
|---|
| Cohort 2: Chinese Participants | 45 Participants |
|---|
| Cohort 1: Japanese Participants | 3 Participants |
|---|
| Cohort 2: Chinese Participants | 5 Participants |
|---|
Part 1: Number of Participants With Potentially Clinically Significant Abnormalities in Laboratory Parameters
Baseline (Day 1) to Week 24 · Participants
| Cohort 1: Japanese Participants | 3 Participants |
|---|
| Cohort 2: Chinese Participants | 1 Participants |
|---|
| Cohort 1: Japanese Participants | 25 Participants |
|---|
| Cohort 2: Chinese Participants | 11 Participants |
|---|
| Cohort 1: Japanese Participants | 15 Participants |
|---|
| Cohort 2: Chinese Participants | 3 Participants |
|---|
Part 1: Number of Participants With Abnormal Shift in 12-Lead Electrocardiogram (ECG) Values
Baseline (Day 1) to Week 24 · Participants
| Cohort 1: Japanese Participants | 5 Participants |
|---|
| Cohort 2: Chinese Participants | 3 Participants |
|---|
BENITIONS で見る
ClinicalTrials.gov の原文を見る
すべての治験
このページは ClinicalTrials.gov の公開データをまとめたものです。医学的助言ではなく、投資助言でもありません。必ず専門医にご相談ください。